Search

Search Results

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  4103

  PDF: 3383

  HTML: 202

• EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES

  Pietro Tralongo, Arianna Bakacs, Luigi Maria Larocca

  e2024042

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.042

  4087

  PDF: 1581

  HTML: 942

• TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi, Dr. Galli, Prof. Patrizia Chiusolo

  e2025039

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.039

  2183

  PDF: 1480

  HTML: 264

• THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

  Francesco Maura, Lucia Farina, Paolo Corradini

  e2016045

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.045

  4036

  PDF: 1146

  HTML: 1934

  Fig.1: 217

  Fig. 2: 110

  Table 1: 201

  Table2: 218

  Table 3: 199

• INFECTIOUS AETIOLOGY OF MARGINAL ZONE LYMPHOMA AND ROLE OF ANTI-INFECTIVE THERAPY

  Salvatore Perrone, Gianna Maria D'Elia, Alessandro Pulsoni

  e2016006

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.006

  4430

  PDF: 1326

  HTML: 2158

• PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations

  Michele Bibas

  e2024007

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.007

  3538

  PDF: 2404

  HTML: 1458

• CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL

  Ugo Testa, Dr. Elvira Pelosi, Dr. Germana Castelli, Dr. Alberto Fresa, Prof. Luca Laurenti

  e2024045

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.045

  3537

  PDF: 1563

  HTML: 80

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2484

  PDF: 836

  HTML: 8819

  Efremov 1: 225

  Efremov 2: 187

• HHVs AND LYMPHOPROLIFERATIVE DISORDERS

  C Quadrelli, P Barozzi, G Riva, Mario Luppi

  e2011043

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.043

  1381

  PDF: 814

  HTML: 3121

• PATHOBIOLOGY OF HODGKIN LYMPHOMA

  Claudio Agostinelli, Stefano Pileri

  e2014040

  2014-06-05

  https://doi.org/10.4084/mjhid.2014.040

  3213

  PDF: 1427

  HTML: 5844

  Fig1-Ag-Pil: 223

  Ag-Pil Fig.2: 227

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3733

  PDF: 1058

  HTML: 1927

• INFECTIONS AND FOLLICULAR LYMPHOMA: IS THERE A LINK?

  Francesco Zallio, Giulia Limberti, Marco Ladetto

  e2017035

  2017-05-01

  https://doi.org/10.4084/mjhid.2017.035

  3221

  PDF: 1007

  HTML: 2023

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4308

  PDF: 1487

  HTML: 1547

  Untitled: 225

• FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT

  Alessia Castellino, Umberto Vitolo

  e2017009

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.009

  4412

  PDF: 1627

  HTML: 3611

  Tables and Images: 218

• OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT

  Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri, Urban Novak, Thomas Pabst

  e2023025

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.025

  1289

  HTML: 305

  PDF: 930

  Suppl. Files: 445

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN FOLLICULAR LYMPHOMAS

  Mónica Cabrero, Alba Redondo, Alejandro Martin, Dolores Caballero

  e2012074

  2012-11-07

  https://doi.org/10.4084/mjhid.2012.074

  2146

  PDF: 730

  HTML: 1069

• IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS

  Alana Kennedy-Nasser, Catherine Bollard, Helen Heslop

  e2009010

  2009-11-13

  https://doi.org/10.4084/mjhid.2009.010

  1163

  PDF: 601

  HTML: 6797

• SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis

  Roberta Zanotti, Massimiliano Bonifacio, Ilaria Tanasi, Donatella Schena, Giovanni Orsolini, Morena Tebaldi, Lara Crosera, Francesca Mastropaolo, Elisa Olivieri, Dr. Patrizia Bonadonna

  e2021068

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.068

  1517

  PDF: 940

  HTML: 222

• COINCIDENCE OR CONNECTION? REVISITING THE RELATIONSHIP BETWEEN MASTOCYTOSIS AND LYMPHOMA

  Antonio Frolli, Cristina Papayannidis, Carmen Fava, Martina Bullo, Selene Grano, Valentina Bonuomo, Daniela Gottardi, Guido Parvis, Beatrice Casadei, Daniela Cilloni

  e2026047

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.047

  143

  PDF: 162

  HTML: 11

• IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS

  Efterpi Kostareli, Maria Gounari, Andreas Agathangelidis, Kostas Stamatopoulos

  e2012052

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.052

  3046

  PDF: 872

  HTML: 7162

  Kost Fig1: 181

  Kost Fig 2: 177

  Kost Fig3: 174

  Kost Fig 4: 188

  Kost Fig5: 184

  Kost fig 6: 173

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  2034

  PDF: 1113

  HTML: 179

• THE TREATMENT OF ADVANCED-STAGE MYCOSIS FUNGOIDES AND SEZARY SYNDROME: A HEMATOLOGIST'S POINT OF VIEW.

  Antonio Giordano, Livio Pagano

  e2022029

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.029

  2065

  PDF: 1016

  HTML: 266

• ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE TREATMENT OF CHRONIC LYMPHOCITIC LEUKEMIA : WHY AND WHEN ?

  Maria L. Delioukina, Stephen J. Forman

  e2010018

  2010-06-30

  https://doi.org/10.4084/mjhid.2010.018

  1229

  PDF: 784

  HTML: 539

• CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma

  Ugo Testa, Francesco D'Alò, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2024012

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.012

  2260

  PDF: 1815

  HTML: 142

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7421

  PDF: 2415

  HTML: 1726

  Table 1.: 208

  Table 2.: 216

  Table 3.: 200

  Table 4.: 199

• Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India

  Mary Theresa Sylvia, Biswajit Dey, Debdatta Basu, Sajini Elizabeth Jacob, Rakhee Kar, Biswajit Dubashi

  e2016060

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.060

  3182

  PDF: 773

  HTML: 2945

  Figure 1a and 1b: 146

  Figure 2: 158

  Figure 3: 176

  Figure 4: 158

  Figure 5: 162

  Tables 1-5: 151

• Coexistence of T-Large Granular Lymphocyte Leukemia and Peripheral T Cell Lymphoma-NOS with indolent behaviour

  Luca Guarnera, Valentina Boldrini, Gianmario Pasqualone, Carolina Cimino, Elisa Meddi, Roberta Laureana, Donata Trivigno, Giovanni Del Poeta, Alessandro Mauriello, Lucia Anemona, Massimiliano Postorino, Maria Cantonetti

  e2022006

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.006

  1625

  PDF: 606

  HTML: 321

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1558

  PDF: 601

  HTML: 188

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

  Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

  e2024061

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.061

  2736

  PDF: 3198

  HTML: 373

• Severe CMV infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in an old mantle cell lymphoma patient

  Gabriele Magliano, Annarosa Cuccaro, Francesco D'Alo', Elena Maiolo, Silvia Bellesi, Stefan Hohaus, Andrea Bacigalupo, Livio Pagano

  e2021054

  2021-08-28

  https://doi.org/10.4084/MJHID.2021.054

  1210

  PDF: 396

  HTML: 145

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2498

  PDF: 1982

  HTML: 200

• IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?

  Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi

  e2017010

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.010

  3361

  PDF: 1277

  HTML: 2215

  Fi.1 Gritti.Rambaldi: 204

• CLASSIC KSHV/HHV-8-POSITIVE PRIMARY EFFUSION LYMPHOMA (PEL): A SYSTEMATIC REVIEW AND META-ANALYSIS OF CASE REPORTS

  Ilaria Cozzi, Giovanni Rossi, Emma Rullo, Valeria Ascoli

  e2022020

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.020

  1531

  PDF: 944

  HTML: 298

• COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.

  Federico Mercolini, Simone Cesaro

  e2022009

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.009

  2256

  PDF: 931

  HTML: 300

• Zanubrutinib as upfront treatment in de-novo B-cell prolymphocytic leukemia: the case of two elderlies.

  Silvia Giorgi, Giovanna Leonardi, Monica Maccaferri, Elena Sbadili, Carlo Caterina, Giovanni Fera, Ambra Paolini, Leonardo Potenza, Anna Candoni, Mario Luppi, Roberto Marasca

  e2025061

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.061

  1141

  PDF: 527

  Html: 115

• HEAVY-CHAIN DISEASES AND MYELOMA-ASSOCIATED FANCONI SYNDROME: AN UPDATE

  Roberto Ria, Franco Dammacco, Angelo Vacca

  e2018011

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.011

  5152

  PDF: 1625

  HTML: 1365

• TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL Sirapat Rungwittayatiwat1, Paisarn Boonsakan2, Pichika Chantrathammachart1, Teeraya Puavilai1, Sulada Pukiat1, Sithakom Phusanti1,3, Kochawan Boonyawat1, Pathawut Wacharapornin1, Pantep Angchaisuksiri1, Artit Ungkanont1,3, Suporn Chuncharunee1 Pimjai Niparuck1

  PIMJAI NIPARUCK

  e2021063

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.063

  1125

  PDF: 516

  HTML: 192

• HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?

  Antoine Thyss, Esma Saada, Lauris Gastaud, Frédéric Peyrade, Daniel Ré

  e2014050

  2014-07-01

  https://doi.org/10.4084/mjhid.2014.050

  2878

  PDF: 1357

  HTML: 3568

  Untitled: 192

  Untitled: 200

  Untitled: 177

• Gamma heavy chain disease associated with T-cell large granular lymphocyte lymphoproliferative disorder: case report and literature review.

  Maria Laura Bisegna, Maria Assunta Limongiello, Stefano Fiori, Maria Stefania De Propris, Irene Della Starza, Stefania Trasarti

  e2023010

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.010

  949

  PDF: 933

  HTML: 443

• PERIPHERAL NERVOUS SYSTEM INVOLVEMENT IN LYMPHOPROLIFERATIVE DISORDERS

  Mario Sabatelli, Luca Laurenti, Marco Luigetti

  e2018057

  2018-09-01

  https://doi.org/10.4084/mjhid.2018.057

  1751

  PDF: 876

  HTML: 373

  Fig1: 230

  Fig.2: 251

  Fig. 3: 180

  Fig. 5: 195

  Fig. 4: 223